Company Overview: Cytori

Industry News

24 Jul

Cytori Announces Top-Line 24- and 48-Week Results from the STAR Trial of Habeo™ Cell Therapy in Patients with Scleroderma

Statistical significance not achieved in primary or secondary efficacy endpoints Clinically meaningful efficacy trends observed in primary and secondary endpoints in pre-specified diffuse cutaneous scleroderma subgroup No significant safety related issues Conference call scheduled for 8:30am EDT  SAN DIEGO, July 24, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX)...

Read more

6 Jul

Cytori Receives Key Cell Therapy Patent for Scleroderma

Strengthens Global Scleroderma Intellectual Property Portfolio Extends E.U. protection through 2034 SAN DIEGO, July 06, 2017 (GLOBE NEWSWIRE) —  Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”) announced today the issuance of key patents that strengthen its intellectual property portfolio in the U.S. and Europe. Cytori now has 107...

Read more

1 Jun

Cytori to Introduce Next-Generation Celution® Technology

SAN DIEGO, June 01, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”), today announced plans to introduce its next-generation Celution® technology.  The technology is available for pre-orders effective June 1st, 2017 with first product shipments anticipated to begin in Q3. The next-generation Celution® technology incorporates...

Read more

31 May

Cytori and BARDA Execute $13.4 Million Contract Option for Burn Clinical Trial

SAN DIEGO, May 31, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (“Cytori” or the “Company”) today announced that the Company and the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), have executed...

Read more

12 May

Cytori Reports First Quarter 2017 Business and Financial Results

SAN DIEGO, May 11, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics (CYTX) (“Cytori” or the “Company”) today announced its first quarter 2017 financial results and provided updates on its corporate activity and clinical development. First quarter 2017 adjusted net loss was $5.9 million, or $0.26 per share, and excludes a...

Read more

8 May

Cytori Therapeutics Announces Inducement Grants for New Employees

SAN DIEGO, May 05, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) (the “Company”), announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options on May 4, 2017 to eight (8) new employees (the “Optionees”) exercisable for an aggregate of up to 24,500...

Read more

28 Apr

Cytori to Webcast First Quarter Financial Results on May 11

SAN DIEGO, April 27, 2017 (GLOBE NEWSWIRE) — Cytori Therapeutics, Inc. (CYTX) will provide a live webcast of its first quarter financial results and business update on Thursday, May 11, 2017 at 5:30 PM Eastern Time. The dial-in information is as follows: Dial-In Number: +1.877.402.3914 Conference ID: 15172159 Prior...

Read more

Page 1 of 712345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address